About olaparib
PARP inhibitor anticancer medicine
Used for
- Treats certain ovarian, fallopian tube, and peritoneal cancers
- Treats certain breast, pancreatic, and prostate cancers
Usual adult dose
Usually 300 mg by mouth twice daily; dose varies by cancer, kidney function, and other medicines.
Common side effects
- Nausea, vomiting, diarrhea, or constipation
- Tiredness, weakness, or reduced appetite
- Anemia and other low blood counts
- Headache or changes in taste
Important warnings
- Can cause serious bone marrow problems, including rare leukemia or myelodysplastic syndrome
- May cause lung inflammation; new breathing problems need prompt assessment
- May harm an unborn baby; effective contraception is required during treatment
- Blood counts and kidney function require monitoring
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for six months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for one month after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase olaparib levels
- Strong or moderate CYP3A inducers can reduce effectiveness
- Avoid grapefruit and Seville oranges, which may alter drug levels
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.